Onset
Not established in humans.
Protocol / Research Dosing Guide
Humanin Dosage Guide: Animal Evidence, Vial Math and Safety
A source-gated Humanin reference that keeps mitochondrial animal research separate from the planning figures circulating in research communities.
Last reviewed September 16, 202615 minute readResearch information only
Level 2 — Animal and laboratory evidenceNo human randomized trialNot FDA approved
Humanin Quick Start
Humanin is a short peptide encoded in mitochondrial DNA and studied as a cytoprotective signal. Almost all quantitative dosing evidence comes from rodent work using the potent HNG analogue, and native humanin and HNG are not interchangeable. No human randomized trial establishes a humanin dose, schedule or cycle.
Why researchers care
Mitochondrial stress signalling, metabolic and neuroprotection research
Class
Mitochondrial-derived peptide; the HNG analogue is the form used in most animal work
Route reported
Subcutaneous or intraperitoneal in published animal work
Cycle length
Not established
Regulatory status
Not FDA approved
Loading supplier information
Humanin Dosing Protocol and Schedule
The supplied source reports animal HNG examples such as 4 mg/kg intraperitoneally twice weekly and 2.5 mg/kg intraperitoneally twice daily for three days, alongside community planning ranges that carry no clinical evidence.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Animal study example | HNG 4 mg/kg intraperitoneally, twice weekly | Animal evidence |
| Animal study example | HNG 2.5 mg/kg intraperitoneally, twice daily for three days | Animal evidence |
| Community planning range | Source-reported daily subcutaneous planning figures | Community reported |
| Human schedule | Not established | Not established |
| Rest period | Not established | Not established |
Animal milligram-per-kilogram figures do not convert to a human amount, and the analogue used in those studies is more potent than native humanin.
Humanin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label
Humanin Reconstitution Calculator
Vial-format concentration math
Concentration
10 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Humanin: Morning or Night?
Time of day?
Not established. No study compares administration times.
Once or split?
Animal studies used study-specific frequencies, not a transferable schedule.
With food?
Not applicable to an injected research vial.
Missed amount?
No validated procedure exists.
Humanin Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Intraperitoneal | The route in most rodent HNG studies | Not a human route |
| Subcutaneous | The route discussed in research-community planning | No human pharmacokinetic study |
| Oral | Not viable for an unprotected peptide | Digestion degrades it |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Humanin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human pharmacokinetic study identified |
| Animal clearance | Rapid clearance reported for native humanin | Species and analogue specific |
| HNG versus native | HNG is reported to be substantially more potent | Not interchangeable |
| Frequency | Not established | Animal frequencies were study design choices |
Humanin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Intraperitoneal (rodent) | 4 mg/kg | Twice weekly | Animal study | No |
| Intraperitoneal (rodent) | 2.5 mg/kg | Twice daily for three days | Animal study | No |
| Subcutaneous (human) | Not established | Not established | No evidence | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Humanin Reconstitution Guide
Concentration: 10 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 1 mg | 0.1 mL | 10 units |
| 2 mg | 0.2 mL | 20 units |
| 3 mg | 0.3 mL | 30 units |
- 1.Confirm the milligram total on the vial label.
- 2.Record the exact bacteriostatic water volume added.
- 3.Clean the stopper with an alcohol swab.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently until dissolved; do not shake.
- 6.Divide milligrams by millilitres for concentration. 20 mg in 2 mL is 10 mg/mL, so 1 mg is 0.1 mL or 10 units.
- 7.Label the concentration and the preparation date.
- 8.Refrigerate and protect from light.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Humanin Works
Origin
Humanin is encoded within the mitochondrial 16S rRNA region and released as a signalling peptide.
Humanin Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved
- No published randomized human trial of humanin or HNG was identified.
- Observational work reports that circulating humanin levels decline with age, which is an association, not an intervention result.
- Quantitative dosing evidence is rodent-derived and analogue specific.
- Humanin is not FDA approved and has no established medical use.
Who Should Avoid Humanin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Active cancer
Cytoprotective signalling in cancer contexts is not characterized in humans
Concurrent medicines
No interaction studies
Any human use
No human safety dataset exists
Humanin Side Effects, Risks and Safety
Injection-site reactionAnecdotal
Important limitation: No controlled incidence data.
Allergic responseUnknown
Important limitation: No characterized human safety dataset.
Metabolic effectsAnimal only
Important limitation: Human relevance not established.
Cancer-context riskUnknown
Important limitation: Cytoprotection has not been evaluated for human risk.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Humanin Timeline and Monitoring
Animal response windows
Study-specific and tied to the model used.
Monitoring
No validated monitoring schedule exists.
Stopping rules
Not established.
Humanin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Mitochondrial protection | Animal and laboratory | Level 2 | Not human evidence |
| Metabolic markers | Animal | Level 2 | No human trial |
| Neuroprotection | Animal and laboratory | Level 2 | No human trial |
| Longevity claims | Not established | Association studies only | No intervention evidence |
Humanin Storage and Handling
Unreconstituted vial
Follow the exact product label; keep cool and dry.
Prepared vial
Refrigerate; no validated humanin-specific stability window was identified.
Freezing
Repeated freeze-thaw cycles are generally avoided for peptide solutions.
Appearance
Cloudiness or particles mean the solution should not be used.
Humanin Troubleshooting
Units look too small
Recheck vial milligrams, liquid volume and the target unit before drawing.
Animal figures seem to convert
They do not. Milligram-per-kilogram animal figures are not a human amount.
Solution appears cloudy
Stop and seek qualified product guidance.
Unexpected symptoms
No humanin safety protocol exists; seek licensed clinical review.
Missed planned administration
No validated procedure exists.
Humanin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Humanin | Native mitochondrial-derived peptide | Animal and laboratory evidence | Not approved |
| HNG analogue | Potency-enhanced research analogue | Most rodent dosing data | Not interchangeable |
| MOTS-c | Separate mitochondrial-derived peptide | Different evidence base | Not interchangeable |
Humanin Frequently Asked Questions
What is humanin?
A short peptide encoded in mitochondrial DNA and studied as a cytoprotective signal.
Is there a human dose?
No. No human trial establishes one.
What is HNG?
A modified, more potent research analogue used in most rodent studies.
Can animal mg/kg figures be converted?
No. They are study-design values in a different species with a different analogue.
Is humanin FDA approved?
No.
What is its half-life in humans?
Not established.
Which route do studies use?
Mostly intraperitoneal in rodents.
Is a cycle length established?
No.
Does declining humanin with age prove a benefit from supplementing it?
No. That is an association, not an intervention result.
What does the calculator do?
Concentration and volume arithmetic only.
Is long-term safety known?
No.
Sources and Research
Coverage source
1. Humanin protocol coverage source
Supplied coverage source for reported animal examples and vial arithmetic.
Open direct sourcePublished review
2. Humanin: a mitochondrial-derived peptide in cytoprotection
Published review of humanin biology and receptor interactions.
Open direct sourceAnimal research
3. HNG analogue rodent studies
Animal work describing HNG administration in metabolic and neuroprotection models.
Open direct sourceMissing information flagged for review
- Human dose: Not established
- Human half-life and bioavailability: Not established
- Validated cycle and rest period: Not established
- Human safety dataset: Not established
- Native humanin versus HNG equivalence: Not established